The latest about the Tenofovir (CAPRISA 004) trial is that it might not have any effect on herpes virus (HSV-2). It was hoped that it might reduce transmission among those using the 1% vaginal gel, but recent evidence suggests this is unlikely. The effectiveness of the gel against HSV-2 was estimated at just over 50%, compared to the 39% claimed for HIV. It makes you wonder how the trial got the results it did for HSV-2. But the same question could equally be asked about the results they got for HIV.
[For more on the medical male circumcision debate, which AVAC and the Gates Foundation are also involved in, see my other blog.]